Literature DB >> 12140548

Screening inhibitors of anthrax lethal factor.

Fiorella Tonello1, Michela Seveso, Oriano Marin, Michèle Mock, Cesare Montecucco.   

Abstract

The disease anthrax is caused by lethal factor, an enzyme component of the toxin produced by the spore-forming bacterium Bacillus anthracis. Here we describe substrate molecules for this factor that offer a means for high-throughput screening of potential inhibitors for use in anthrax treatment. Our assay should help to answer the urgent call for new and specific therapies to combat this pathogen after its recent emergence as a terrorist bioweapon.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12140548     DOI： 10.1038/418386a

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


  37 in total

1.  Protection against anthrax toxemia by hexa-D-arginine in vitro and in vivo.

Authors:  Miroslav S Sarac; Juan R Peinado; Stephen H Leppla; Iris Lindberg
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

2.  Characterization of MtfA, a novel regulatory output signal protein of the glucose-phosphotransferase system in Escherichia coli K-12.

Authors:  Anna-Katharina Göhler; Ariane Staab; Elisabeth Gabor; Karina Homann; Elisabeth Klang; Anne Kosfeld; Janna-Eleni Muus; Jana Selina Wulftange; Knut Jahreis
Journal:  J Bacteriol       Date:  2011-12-16       Impact factor: 3.490

3.  Inhibition of anthrax lethal factor: lability of hydroxamate as a chelating group.

Authors:  Feng Li; Irina Chvyrkova; Simon Terzyan; Nancy Wakeham; Robert Turner; Arun K Ghosh; Xuejun C Zhang; Jordan Tang
Journal:  Appl Microbiol Biotechnol       Date:  2012-01-25       Impact factor: 4.813

4.  Gold nanoparticles-based protease assay.

Authors:  Cristian Guarise; Lucia Pasquato; Vincenzo De Filippis; Paolo Scrimin
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-01       Impact factor: 11.205

Review 5.  The biology and future prospects of antivirulence therapies.

Authors:  Lynette Cegelski; Garland R Marshall; Gary R Eldridge; Scott J Hultgren
Journal:  Nat Rev Microbiol       Date:  2008-01       Impact factor: 60.633

Review 6.  Targeting Metalloenzymes for Therapeutic Intervention.

Authors:  Allie Y Chen; Rebecca N Adamek; Benjamin L Dick; Cy V Credille; Christine N Morrison; Seth M Cohen
Journal:  Chem Rev       Date:  2018-09-07       Impact factor: 60.622

7.  Evaluation of IRES-mediated, cell-type-specific cytotoxicity of poliovirus using a colorimetric cell proliferation assay.

Authors:  Xiaoyi Yang; Eying Chen; Hengguang Jiang; Karen Muszynski; Raymond D Harris; Steven L Giardina; Matthias Gromeier; Gautam Mitra; Gopalan Soman
Journal:  J Virol Methods       Date:  2008-11-08       Impact factor: 2.014

8.  Identification of exosite-targeting inhibitors of anthrax lethal factor by high-throughput screening.

Authors:  Ludovic Bannwarth; Allison B Goldberg; Catherine Chen; Benjamin E Turk
Journal:  Chem Biol       Date:  2012-07-27

9.  Selective inhibition of anthrax edema factor by adefovir, a drug for chronic hepatitis B virus infection.

Authors:  Yuequan Shen; Natalia L Zhukovskaya; Michael I Zimmer; Sandriyana Soelaiman; Pamela Bergson; Chyung-Ru Wang; Craig S Gibbs; Wei-Jen Tang
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-20       Impact factor: 11.205

10.  Small molecule inhibitors of anthrax lethal factor toxin.

Authors:  John D Williams; Atiyya R Khan; Steven C Cardinale; Michelle M Butler; Terry L Bowlin; Norton P Peet
Journal:  Bioorg Med Chem       Date:  2013-11-13       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.